Core Insights - The company reported a significant decline in revenue and net profit for the year 2024, with total revenue of 275 million yuan, a decrease of 42.77% year-on-year, and a net loss of approximately 20 million yuan compared to a profit of nearly 100 million yuan in the previous year [1][3] - For the first quarter of 2025, the company continued to experience a decline in revenue, reporting 40 million yuan, down 45.87% year-on-year, and a net loss of about 10.8 million yuan compared to a profit of over 10 million yuan in the same period last year [1][4] - The company has proposed no cash dividends, stock bonuses, or capital increases for the 2024 profit distribution plan [1] Financial Performance Summary - **2024 Annual Report:** - Revenue: 275 million yuan, down 42.77% from 480 million yuan in 2023 [3] - Net Profit: -20 million yuan, down 120.02% from 100 million yuan in 2023 [3] - Net Profit (excluding non-recurring items): -26 million yuan, down 130.15% from 87 million yuan in 2023 [3] - Operating Cash Flow: 56.6 million yuan, down 49.00% from 110.9 million yuan in 2023 [3] - **2025 Q1 Report:** - Revenue: 40 million yuan, down 45.87% from 74 million yuan in Q1 2024 [4] - Net Profit: -10.8 million yuan, down 202.7% from 10.5 million yuan in Q1 2024 [4] - Net Profit (excluding non-recurring items): -14.4 million yuan, down 268.83% from 8.5 million yuan in Q1 2024 [4] - Operating Cash Flow: 29.7 million yuan, up 187.24% from 10.3 million yuan in Q1 2024 [4] Company Background - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 3, 2019, with an initial issuance of 20.9 million shares at a price of 24.79 yuan per share [4] - The total amount raised from the initial public offering was approximately 51.8 million yuan, with a net amount of about 45.7 million yuan after deducting issuance costs [5]

Core Viewpoint - The photovoltaic industry is undergoing significant adjustments due to supply-demand mismatches, leading to a reduction in workforce across many companies [1][3][4]. Group 1: Workforce Changes - The number of employees in 109 A-share photovoltaic companies is projected to decrease from 78,260 in 2023 to 63,870 in 2024, indicating a reduction of over 14,000 employees [1][4]. - The workforce saw a substantial increase from 61,770 in 2022 to 78,260 in 2023, driven by a surge in industry performance, with total revenue reaching 1.65 trillion yuan and net profit hitting 147.09 billion yuan in 2023 [2][4]. - Major companies like Longi Green Energy, Jinko Solar, Trina Solar, and JA Solar have reduced their workforce by over 10,000 employees each, with Longi and Jinko seeing reductions exceeding 20,000 [5]. Group 2: Financial Performance - The financial performance of the photovoltaic industry is expected to decline in 2024, with total revenue dropping to 1.38 trillion yuan and a net loss of 60 million yuan reported [4]. - The decline in material prices has led to some companies operating at a loss, prompting them to implement cost-cutting measures, including workforce reductions [3][4]. Group 3: Contrasting Trends - Despite the overall trend of workforce reduction, some companies, particularly in the photovoltaic equipment sector, are hiring. For instance, North China Innovation added 4,434 employees, and Sungrow Power increased its workforce by 3,608 [6]. - Companies producing photovoltaic inverters and auxiliary materials, such as Sungrow, Deye, and Jinlang Technology, have reported overall profitability, allowing them to expand their workforce [6].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 迈得医疗工业设备股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的 公告 证券代码：688310 证券简称：迈得医疗 公告编号：2025-020 投资者可于 2025 年 5 月 9 日（星期五）至 5 月 15 日（星期四）16:00 前通过 公司邮箱（zq@maiderchina.com)进行提问。公司将在说明会上对投资者普遍关 注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2025 年 5 月 29 日（星期四）09:30-10:30 （ 二 ） 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： https://roadshow.sseinfo.com/） （三） 会议召开方式：上证路演中心视频录播和网络互动 三、 参加人员 董事长、总经理：林军华先生 迈得医疗工业设备股份有限公司（以下简称"公司"）已于 2025 年 4 月 30 日 发布公司 2024 年度报 ...

近日迈得医疗披露，截至2025年3月31日公司股东户数为3997.0户，较12月31日增加163.0户，增幅为 4.25%。户均持股数量由上期的4.34万股减少至4.16万股，户均持股市值为48.66万元。 业绩披露要点 截至2025年4月30日收盘，迈得医疗(688310)报收于11.23元，上涨2.74%，换手率0.92%，成交量1.54万 手，成交额1725.3万元。 当日关注点 交易信息汇总 4月30日主力资金净流出425.85万元，占总成交额24.68%；游资资金净流出187.51万元，占总成交额 10.87%；散户资金净流入613.36万元，占总成交额35.55%。 股本股东变化 迈得医疗2024年年报显示，公司主营收入2.75亿元，同比下降42.77%；归母净利润-1998.12万元，同比 下降120.02%；扣非净利润-2628.09万元，同比下降130.15%；其中2024年第四季度，公司单季度主营收 入5527.67万元，同比下降63.22%；单季度归母净利润-2761.11万元，同比下降198.39%；单季度扣非净 利润-2658.07万元，同比下降210.59%；负债率19.74%，投 ...

Company Performance - Maider Medical achieved an annual revenue of 275 million yuan with a comprehensive gross margin of 43.56% [1] - Revenue from blood purification and safe infusion line machines reached 104 million yuan and 116 million yuan, with gross margins of 51.81% and 39.44% respectively [1][3] - The company reported a 39.38% year-on-year increase in overseas revenue, totaling 17.63 million yuan, with a gross margin of 44.90%, surpassing domestic sales by 1.43 percentage points [3] R&D and Innovation - The company invested 40.41 million yuan in R&D, a 21.81% increase year-on-year, accounting for 14.70% of total revenue [1][5] - Maider Medical submitted 146 patent applications during the reporting period, including 21 invention patents, and received 78 new patent authorizations [5] - The company has a total of 416 authorized patents, including 195 invention patents, and has actively participated in drafting national and provincial standards [5][7] Market Position and Strategy - Maider Medical is recognized as a leading supplier of dialysis consumables and has maintained the highest market share in the industry for three consecutive years from 2021 to 2023 [3] - The company is focusing on expanding its product matrix in the contact lens business and has successfully obtained multiple medical device registration certificates [4] - The company aims to enhance its operational efficiency and expand its medical equipment industry chain by advancing its smart medical consumables project and technology center [4][6] Industry Trends - The global medical device market reached a size of 582.6 billion USD in 2023, growing by 5.40% year-on-year, while China's market exceeded 1 trillion yuan, reaching 1,032.8 billion yuan [2] - The medical device industry is transitioning towards high-quality development, driven by policy support, market expansion, and automation in production [2] - The company is positioned to leverage the opportunities presented by the aging population and the advancement of manufacturing strategies in China [1][2]

Company Overview - Midea Medical's stock closed at 11.23 yuan, up 2.74%, with a latest price-to-book ratio of 2.38, marking a new low in 19 days, and a total market capitalization of 1.867 billion yuan [1] - As of the first quarter of 2025, five institutions held shares in Midea Medical, including three funds, one other entity, and one social security fund, with a total holding of 15.2835 million shares valued at 17.9 million yuan [1] Business Operations - Midea Medical Industrial Equipment Co., Ltd. specializes in the research, development, production, sales, and service of medical consumables and intelligent equipment [1] - The company's main products include two categories: safety infusion devices and blood purification equipment [1] - Midea Medical has been recognized with qualifications such as the establishment of a postdoctoral workstation in Zhejiang Province and participation in various provincial projects aimed at transforming manufacturing methods and R&D initiatives [1] Financial Performance - In the latest financial report for the first quarter of 2025, Midea Medical reported operating revenue of 40.1763 million yuan, a year-on-year decrease of 45.87% [1] - The company recorded a net loss of approximately 10.797 million yuan, representing a year-on-year decline of 202.70%, with a sales gross margin of 32.89% [1] Industry Comparison - Midea Medical's price-to-earnings ratio (TTM) is -45.21, while the industry average is 57.80, indicating significant underperformance compared to peers [2] - The company's market capitalization stands at 1.867 billion yuan, which is lower than the industry median of 3.727 billion yuan [2]

Core Viewpoint - The company, Maider Medical Equipment Co., Ltd., has announced its financial and operational updates, including a share buyback plan and the upcoming annual shareholder meeting. Financial Data - The company reported that as of March 31, 2025, it had repurchased a total of 2,592,575 shares, representing 1.5597% of its total share capital of 166,219,690 shares, with a total expenditure of approximately RMB 29.16 million [8]. - The maximum repurchase price was set at RMB 15 per share, with a total repurchase fund amounting to no less than RMB 15 million and not exceeding RMB 30 million [7][8]. Shareholder Information - The company plans to hold its 2024 annual shareholder meeting on May 20, 2025, at 13:30, with both onsite and online voting options available [69]. - The meeting will address various proposals, including the 2024 annual financial report and the election of new board members [71][72]. Cash Management - The company intends to use up to RMB 30 million of its idle funds for cash management, aiming to enhance fund utilization efficiency while ensuring normal operational liquidity [54][61]. - The cash management products will be selected from reputable financial institutions, focusing on high safety and liquidity [58][62]. Board and Supervisory Committee Activities - The company’s supervisory committee approved several key proposals, including the 2024 annual financial report and the internal control evaluation report, which will be submitted for shareholder approval [15][20][38]. - The committee also discussed the election of new supervisory board members, with nominations for candidates already made [46][48].

迈得医疗工业设备股份有限公司 2024 年度独立董事述职报告 迈得医疗工业设备股份有限公司 本人作为迈得医疗工业设备股份有限公司（以下简称"公司"）的独立董事， 2024年度严格按照《公司法》《证券法》《上市公司独立董事管理办法》等法律 法规及《公司章程》《独立董事工作制度》等规定，忠实、勤勉地履行独立董事 职责，认真了解公司运作情况，审议董事会及相关专门委员会等各项议案，对相 关事项发表独立意见，充分发挥独立董事的作用，维护公司和全体股东尤其是中 小股东的合法权益。现将2024年度履职情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 何涛：1962年12月出生，中国国籍，无境外永久居留权，武汉测绘学院光学 测绘仪器专业工学学士，教授级高级工程师。2013年获得国务院政府特殊津贴， 中国标准创新贡献奖获得者。曾任职于浙江省医疗器械研究所、浙江省医疗器械 检验所。现任浙江省医疗器械行业协会会长、杭州美迪同创技术咨询有限公司董 事兼总经理、宁波海尔施基因科技股份有限公司董事、东点科脉(杭州)科技有限 公司董事、浙江优亿医疗器械股份有限公司独立董事，2022年5月起任公司独立 董事。 ...

迈得医疗工业设备股份有限公司 2024 年度独立董事述职报告 迈得医疗工业设备股份有限公司 2024 年度独立董事述职报告 本人作为迈得医疗工业设备股份有限公司（以下简称"公司"）的独立董事， 2024年度严格按照《公司法》《证券法》《上市公司独立董事管理办法》等法律 法规及《公司章程》《独立董事工作制度》等规定，忠实、勤勉地履行独立董事 职责，认真了解公司运作情况，审议董事会及相关专门委员会等各项议案，对相 关事项发表独立意见，充分发挥独立董事的作用，维护公司和全体股东尤其是中 小股东的合法权益。现将2024年度履职情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 张颖辉：1985年1月出生，中国国籍，无境外永久居留权，杭州电子科技大 学财务管理管理学学士，高级会计师、注册会计师、注册税务师。曾任职于天健 会计师事务所（特殊普通合伙）高级项目经理、浙江泰隆商业银行股份有限公司 投资经理、滨海润华环保工程有限公司董事长。主要从事财务管理、内部审计等 工作，具备多年财务管理工作经验。现任浙江吉华集团股份有限公司财务总监， 江苏康倍得药业股份有限公司董事、杭州临江环保热电有限公司监 ...

迈得医疗工业设备股份有限公司 2024 年度独立董事述职报告 迈得医疗工业设备股份有限公司 2024 年度独立董事述职报告 本人作为迈得医疗工业设备股份有限公司（以下简称"公司"）的独立董事， 2024年度严格按照《公司法》《证券法》《上市公司独立董事管理办法》等法律 法规及《公司章程》《独立董事工作制度》等规定，忠实、勤勉地履行独立董事 职责，认真了解公司运作情况，审议董事会及相关专门委员会等各项议案，对相 关事项发表独立意见，充分发挥独立董事的作用，维护公司和全体股东尤其是中 小股东的合法权益。现将2024年度履职情况报告如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景以及兼职情况 王亚卡：1957年12月出生，中国国籍，无境外永久居留权，南京工学院无线 电设备结构与工艺工学学士，高级工程师。曾任职于轻工业部自动化研究所(现 更名为中建材智能自动化研究院有限公司)。现任杭州华澜微电子股份有限公司 独立董事、浙江今飞凯达轮毂股份有限公司独立董事，2022年5月起任公司独立 董事。 （二）独立性说明 作为公司的独立董事，本人不在公司担任除独立董事及董事会各相关专门委 员会成员外的其他职务，并与公司 ...